“Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S57, https://doi.org/10.25251/skin.2.supp.57.